Regenxbio Inc.
Clinical trials sponsored by Regenxbio Inc., explained in plain language.
-
New gene therapy hopes to slow duchenne muscular dystrophy in boys
Disease control Recruiting nowThis study tests a one-time gene therapy called RGX-202 for boys with Duchenne muscular dystrophy (DMD). The therapy aims to help muscles work better by delivering a special protein. About 65 boys aged 1 to 12 will take part. The main goals are to check safety and see if the ther…
Phase: PHASE2, PHASE3 • Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated May 17, 2026 09:18 UTC
-
Blood test may open door to gene therapy for duchenne boys
Knowledge-focused Recruiting nowThis study is a simple blood test to check if boys and young men with Duchenne muscular dystrophy have antibodies against a virus used in gene therapy. It aims to find who might be eligible for future gene therapy trials. Up to 200 participants aged 0 to under 25 will be enrolled…
Sponsor: REGENXBIO Inc. • Aim: Knowledge-focused
Last updated May 08, 2026 12:01 UTC